Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C

NCT01327729 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Self Efficacy
Hepatitis C

Interventions

DRUG: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg

Sponsor

BioGeneric Pharma

Collaborators

[object Object]